Showing 2761-2770 of 4166 results for "".
- University of Minnesota Seeks to Enroll Health Care Workers for COVID-19 Clinical Trialhttps://modernod.com/news/university-of-minnesota-seeks-to-enroll-health-care-workers-for-covid-19-clinical-trial/2477477/The University of Minnesota is launching a clinical trial on a post-exposure treatment for coronavirus COVID-19 disease. This trial is testing hydroxychloroquine, an FDA-approved medicine for the prevention and treatment of malaria, available since the 1950s and known
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- Study Finds Fewer Than Half of US Clinical Trials Complied With New Regulations on Reporting Resultshttps://modernod.com/news/study-finds-fewer-than-half-of-us-clinical-trials-complied-with-new-regulations-on-reporting-results/2477242/According to research published in The Lancet on Friday, compliance with US regulations requiring clinical trials to report results within 1 year of completion remains poor, with about one
- Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/2476977/Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically sig
- Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for Wet AMDhttps://modernod.com/news/kodiak-sciences-to-release-durability-data-from-clinical-development-program-of-ksi-301-for-wet-amd/2476877/Kodiak Sciences announced that updated data from the clinical development program for its investigational therapy KSI-301 will be presented at The Retina Society Annual Meeting on September 15 in London. “Developing intra
- Oyster Point Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/2476763/Oyster Point Pharma announced enrollment of the first subject in the phase 3 ONSET-2 clinical trial of OC-01 nasal spray for the treatment of the signs and symptoms of dry eye disease. “After successfully compl
- Avedro Completes Enrollment in Pivotal US Phase 3 Epi-On Corneal Cross-Linking Clinical Trial for Progressive Keratoconushttps://modernod.com/news/avedro-completes-enrollment-in-pivotal-us-phase-3-epi-on-corneal-cross-linking-clinical-trial-for-progressive-keratoconus/2476526/Avedro announced that the company has completed patient enrollment in a pivotal phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on (Epi-On) corneal cross-linking procedure for the treatment
- LEH Pharma Appoints Syneos Health as Global Clinical Development and Commercialization Solutions Providerhttps://modernod.com/news/leh-pharma-appoints-syneos-health-as-global-clinical-development-and-commercialization-solutions-provider/2479769/LEH Pharma, a provider of ocular implants for macular disorders, announced the selection of Syneos Health, a fully integrated biopharmaceutical solutions organization, as its global clinical development and commercialization provider. The primary aim of the strategic relationship is to acc
- Clearside Biomedical Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of CLS-TA in RVOhttps://modernod.com/news/clearside-biomedical-announces-completion-of-patient-enrollment-in-first-of-two-phase-3-clinical-trials-of-cls-ta-in-retinal-vein-occlusion/2480092/Clearside Biomedical announced completion of patient enrollment in a phase 3 clinical trial of suprachoroidal CLS-TA used in combination with intravitreally administered Eylea (aflibercept) for the treatment of retinal vein occlusion (RVO). SAPPHIRE, a multi
- Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR Implanthttps://modernod.com/news/allergan-announces-positive-topline-phase-3-clinical-data-for-bimatoprost-sr-implant/2480095/Allergan announced the release of new topline clinical trial data on Bimatoprost SR, a sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Bim